Prescription Fish Oil, Lovaza, May Increase Your Risk of Prostate Cancer

According to a study by the Fred Hutchinson Research Center, there is a link between high concentrations of omega-3 fatty acids and an increased risk of prostate cancer.

Lovaza is a prescription fish oil supplement produced by GlaxoSmithKline (“GSK”) combining ethyl esters of omega 3 fatty acids, principally EPA and DHA. Despite over-the-counter alternatives, Lovaza is extremely profitable, grossing over a billion dollars per year. Unfortunately, these recent studies have confirmed that Lovaza is not only costly to consumers’ wallets, but may be costly to their health.

A study published in the Journal of the National Cancer Institute found that high concentrations of EPA, DPA and DHA, the three anti-inflammatory and metabolically related fatty acids derived from fatty fish and fish supplements such as GSK’s Lovaza, are associated with a 71 percent increased risk of high-grade prostate cancer. The study also found a 44 percent increase in the risk of low-grade prostate cancer and an overall 43 percent increase in risk for all prostate cancers. Alan Kristal, study author and member of the Fred Hutchinson Research Center explained “[w]e’ve shown once again that use of nutritional supplements may be harmful.” Kristal also noted a recent analysis published in the Journal of the American Medical Association that questioned the benefit of omega-3 supplementation for cardiovascular diseases. The analysis, which combined data from 20 studies, found no reduction in all-cause mortality, heart attacks, or stocks.

Despite this recent study published in July of 2013, the fish oil and prostate link should not be news for GSK. In fact, this only confirmed a 2011 study involving more than 3,400 men linking a high percentage of omega-3 fatty acid in blood to an increased risk of aggressive prostate cancer. This 2011 study, also published by the same Fred Hutchinson scientific team, revealed that DHA more than doubled the risk of developing high-grade prostate cancer. Despite these findings, Lovaza’s warning label fails to alert consumers to these increased risk of prostate cancer.

If you or a loved one was taking Lovaza and developed prostate cancer, you may have a legal claim against GlaxoSmithKline. You can contact our law firm for a free consultation at (610) 941-4204 or on our website: www.pbmattorneys.com